Invested and incubated by Viva Bioinnovator, ABM Therapeutics, who focuses on the development of small molecule drugs that can break through the blood-brain barrier, announced that the company has recently completed a $20 million round of A + financing. This round of financing will be used to accelerate the clinical research and development of ABM-1310 and several existing preclinical projects, further enrich the R & D pipeline, and create sustainable value in the R&D of small molecules that can break through the blood-brain barrier.
ABM Therapeutics was founded in 2015, which is a small molecule innovative drug research and development platform in clinical stage. Dr. Chen Chen, the founder of The Company, has more than 20 years of experience in the R&D of central nervous system drugs. The team members also have more than 15 years' working experience in the field of biomedicine, with rich experience in drug discovery, biology, clinical research, project management and operation.